OPEN Research Support
head

Physician
Anette Stolberg Kargo
Department of Oncology, Odense University Hospital


Projekt styring
Projekt status    Sampling ongoing
 
Data indsamlingsdatoer
Start 01.10.2016  
Slut 31.12.2021  
 



Individual survivorship program for ovarian cancer patients based on PROM's and shared decision making - PROMova

Short summary

The use of PROM (Patient Reported Outcome Measures) could potentially enhance the understanding of patients' preferences and needs in their follow-up program and thereby improve the quality of life of women with ovarian cancer. To our knowledge PROMova is the first trial to evaluate the use of PROMs during follow-up, and this study aims to assess the feasibility of using PROMs during follow-up and to make a recommendation on the use of PROMs among ovarian cancer survivors, including potential for clinical implementation of PROMs after the research period.


Rationale

Approximately 500 women are diagnosed with ovarian cancer each year and 70-80% will have advanced disease at the time of diagnosis. Despite excellent response to chemotherapy 80-85% of the patients will experience a relapse and the clinical symptoms of relapse can be diffuse. In 2015 the Danish Health Authorities initiated major changes in the follow-up programs for these patients as routine monitoring is ineffective and that follow-up should be individualized. Patient Reported Outcome Measures (PROMs) and Shared Decision Making can help health professionals develop a more individualized care plan in collaboration with the patient, as stated in the revised national follow-up program. Due to the complexity and challenges within ovarian cancer care, this is an evident area of focus. PROMs are tools designed to improve the focus on patients' needs and symptoms, but little is known about their use during cancer follow-up, especially regarding patients' preferences and needs.   


Description of the cohort

Women diagnosed with ovarian cancer who have completed first line treatment and entered follow up are being recruited to the study, including those receiving Bevacizumab treatment, and all oncology departments in Denmark have been invited to participate in PROMova. 


Data and biological material

  • Clinical data - regarding identification, cancer type, FIGO stage, type of treatment
  • Demographic questionnaire - regarding age, educational level, social status, children, knowledge about there disease
  • EORTC-QLQ-C30 - regarding quality of life
  • EORTC-OV28 - regarding late side effect
  • Additional questionnaire - regarding recurrence symptoms
  • CollaboRATE - regarding involvement in decision making


Collaborating researchers and departments

Department of Oncology, Vejle Hospital

  • Consultant Karina Dahl Steffensen
  • Parvin Adimi, MD
Center Lillebaelt, Department of Oncology, Vejle Hospital

  • Professor Angela Coulter
Regional Hospital West Jutland, Herning

  • Professor Niels Henrik I. Hjøllund
Department of Gynaecology and Obstetrics, Odense University Hospital

  • Consultant Pernille T. Jensen, MD, PhD
Department of Gynaecology and Obstetrics, Rigshospitalet, Copenhagen

  • Berit Jul Moesgaard, MD

Department of Oncology, Rigshospitalet, Copenhagen

  • Trine Juhler-Nøttrup, MD
Department of Oncology, Herlev Hospital
  • Nicoline Raaschou-Jensen, MD
Department of Oncology, Zealand University Hospital, Roskilde
  • Benedikte Hasselbalch, MD
Department of Oncology, Aarhus University Hospital
  • Mette Hæe, MD
Department of Oncology, Regional Hospital West Jutland, Herning
  • Rene Olesen, MD
Department of Oncology, Aalborg University Hospital
  • Bente Lund, MD
Women with reproductive cancers, KIU, Danish Cancer Society